Aquilon proves the high potential of HP-Betadex in Dry Powder formulation

The BioWin-funded Aeronext research project has reached its mid-term milestone, confirming the clinical and technological potential of HP-Betadex formulations for dry powder inhalers.

Well-known active pharmaceutical ingredients, mainly used for the treatment of asthma and COPD, formulated with Aquilon’s propriety technology, achieve higher efficacy compared to lactose-based formulations.

This unique and patented formulation technology achieves 79% deposition of the fine particle fraction and 70% deposition of the expired fraction using a standard inhaler device, representing a breakthrough in inhalation therapy.

These key data represent an important step forward in confirming Aquilon Pharma’s potential in the development of formulations for dry powder inhalers.

As a result, Aquilon can now move forward with great confidence with dry powder formulations of novel and biologic treatments to be delivered by inhalation.

Share this article

Share this article on your networks to share it with your friends

More Highlight, R&D news